Musselwhite, Laura W.
Redding, Thomas S. IV
Sims, Kellie J.
O’Leary, Meghan C.
Hauser, Elizabeth R.
Hyslop, Terry
Gellad, Ziad F.
Sullivan, Brian A.
Lieberman, David
Provenzale, Dawn
Funding for this research was provided by:
U.S. Department of Veterans Affairs (N/A)
Duke Cancer Institute (N/A)
U.S. Department of Veterans Affairs Health Services Research and Development (CDA 14-158)
Article History
Received: 22 May 2019
Accepted: 24 September 2019
First Online: 12 November 2019
Ethics approval and consent to participate
: The Durham Veterans Affairs (VA) Medical Center Institutional Review Board approved the Cooperative Studies Program (CSP) #380 study and this secondary analysis under CSP #380 (MIRB #0024): Prospective Evaluation of Risk Factors for Large (1 ≥ cm) Colonic Adenomas in Asymptomatic Subjects. Individual written informed consent was previously obtained during initial recruitment for the CSP #380 (MIRB #0024) protocol.
: Not applicable.
: Terry Hyslop reports fees for serving as an advisory board member on a lung registry trial funded by Astra Zeneca. David Lieberman reports fees for serving as an advisory board member of Motus GI. All other co-authors report no competing interests.